Key Takeaways
- Compounding pharmacies exist to prepare patient-specific formulations that mass-manufactured drugs cannot cover — different doses, alternative routes, allergen-free bases, or combinations.
- U.S. compounding is regulated in two tiers: 503A pharmacies dispense patient-specific prescriptions, and 503B outsourcing facilities operate under cGMP and can distribute in bulk to clinics.
- The FDA's 2024–2025 decisions on tirzepatide and semaglutide "resolved" shortage status, sharply restricting large-scale compounded GLP-1 production. Individualized compounding for legitimate clinical reasons continues.
- Quality varies dramatically. Certificates of Analysis, third-party potency and sterility testing, and USP <797>/<800> compliance are the minimum documentation any patient or clinician should expect.
- Personalization has real clinical value; regulatory grey areas do not disappear because a service is convenient.
What compounding actually is
A compounding pharmacy prepares a medication tailored to an individual patient — typically when the commercially manufactured version is unavailable, inappropriate, or non-existent for that patient's clinical situation. That could mean:
- A pediatric dose of an adult medication that only comes in a fixed strength.
- An oral suspension of a drug that ships only as a tablet, for a patient who cannot swallow.
- A dye-free or preservative-free formulation for a patient with a documented allergy.
- A combination cream that pairs two active ingredients a physician wants delivered together.
- Bio-identical hormone therapy or peptide preparations that require patient-specific dosing.
Compounding is not a shortcut around drug approval. It is a long-standing pharmacy practice that predates the modern pharmaceutical industry — and it is regulated accordingly.
The 503A / 503B distinction
The U.S. compounding landscape is defined by two sections of the Federal Food, Drug, and Cosmetic Act, both added or clarified by the 2013 Drug Quality and Security Act (DQSA) after the 2012 New England Compounding Center meningitis outbreak.
| Feature | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Primary role | Patient-specific prescriptions | Bulk compounding for clinics/hospitals |
| Requires patient-specific Rx? | Yes (per patient) | No |
| Regulatory oversight | State boards of pharmacy + FDA | Registered with and inspected by FDA |
| Manufacturing standard | USP <795> / <797> / <800> | cGMP (current Good Manufacturing Practice) |
| Bulk substances allowed | FDA §503A bulks list | FDA §503B bulks list (narrower) |
| Adverse event reporting | Limited | Mandatory to FDA |
Both tiers are legitimate. The difference matters because the standards, oversight, and scale differ dramatically. A patient receiving a compounded medication is entitled to know which category their pharmacy operates in.
Why personalization matters clinically
For a subset of patients, a mass-produced medication genuinely does not fit. Consider:
- A patient starting a GLP-1 agonist who cannot tolerate the standard titration schedule and needs an intermediate dose the manufacturer does not sell.
- A patient on hormone replacement therapy whose lab values sit between two commercial strengths.
- A patient with documented sensitivity to an inactive ingredient — polysorbate 80, benzyl alcohol, a specific dye — used in the branded product.
- A clinician managing chronic pain who wants a topical rather than systemic route for a well-characterized molecule.
These are not fringe cases. They are the reason compounding exists as a regulated pharmacy discipline.
What the 2024–2025 GLP-1 decisions changed
The most visible recent shift is the FDA's handling of the GLP-1 shortages. When semaglutide and tirzepatide were placed on the FDA drug shortage list, compounding pharmacies were permitted — under §503A and §503B rules for shortage drugs — to prepare compounded versions of the active ingredients for patient-specific prescriptions and for outsourcing to clinics. Demand was enormous.
Beginning in late 2024 and through 2025, the FDA announced that the tirzepatide and semaglutide shortages were resolved and gave compounders wind-down timelines to cease large-scale production of copies. Litigation followed, and the final operational picture continues to evolve. Two things are clear:
- Bulk "off-the-shelf" compounded GLP-1 copies are no longer broadly permitted for the resolved-shortage molecules once wind-down periods end.
- Patient-specific clinical compounding remains available when a documented individualized need exists that the commercial product cannot meet — a genuinely different dose, an allergy to an excipient, or another medically justified reason.
The distinction that matters is personalization vs replication. The FDA's concern with the shortage-era practices was primarily replication at scale — not personalization for patients whose situation the branded product does not cover.
How to evaluate a compounding pharmacy
Quality varies enormously across the industry. Before accepting a compounded preparation, a patient or clinician can and should ask:
| Question | What to look for |
|---|---|
| Are you 503A or 503B? | Clear, documented answer with registration details |
| Do you follow USP <795>, <797>, and <800>? | Yes, with documentation available |
| Do you provide a Certificate of Analysis per lot? | Yes — potency, purity, sterility, endotoxin |
| Who performs the third-party testing? | An independent, ISO-accredited analytical lab |
| Where is the active pharmaceutical ingredient (API) sourced from? | FDA-registered manufacturer; documentation available |
| What is the beyond-use date (BUD) methodology? | USP-based, not arbitrary |
| Are adverse events tracked and reportable? | Yes |
If a pharmacy cannot answer these questions clearly, that is itself an answer. Legitimate operators expect the questions and have documentation ready.
Sourcing and identity: the API problem
Compounded products are only as good as the raw active pharmaceutical ingredient they start with. API sourcing is where quality most often breaks down: unverified suppliers, undocumented synthesis routes, and low-quality identity confirmation can put a preparation on the market that is technically compounded but functionally unreliable.
For peptides specifically, this is compounded (no pun intended) by the difficulty of accurate identity confirmation. HPLC purity and mass-spectrometry identity checks are the minimum expectation for any peptide preparation entering the compounded supply chain. This is also why the research-peptide market — a separate, non-clinical channel — places heavy emphasis on batch-level analytical documentation from suppliers such as Spider Guard Supplements; the same analytical rigor is the baseline expectation for legitimate compounded clinical peptides.
Peptides and the compounding channel
Not all peptides can be compounded lawfully in the U.S. under §503A or §503B. The FDA maintains lists of bulk substances that may be used in compounding, and the 2023 category-2 designations narrowed access to several previously common research peptides. In practice:
- Some peptides remain compoundable under specific rules.
- Some peptides are no longer permitted as bulks for compounding, even when a prescription exists.
- The rules differ for §503A vs §503B.
For the current, authoritative status of a specific peptide, the FDA's bulks lists and category designations are the correct primary source. See our peptide regulation update for the broader context.
Current Evidence
| Domain | State of the field | Confidence |
|---|---|---|
| Clinical value of individualized dosing | Established for hormones, pediatrics, allergies | High |
| Quality variance across pharmacies | Well-documented in FDA warning letters | High |
| GLP-1 compounded copies vs branded outcomes | Emerging, mostly observational | Low–Moderate |
| Long-term safety of compounded peptides | Inconsistent documentation | Low |
| Impact of tightened bulks-list rules on access | Ongoing | Moderate |
Editorial Perspective
Compounding pharmacy is one of the most misunderstood corners of American healthcare. It is neither the villain of the drug-safety story (as some FDA critics frame it) nor the free-market hero (as some telehealth marketers imply). It is a regulated pharmacy discipline with genuine clinical value and genuine quality variance.
Two honest observations from the recent cycle:
First, a meaningful share of the 2023–2025 compounded GLP-1 boom was driven by cost and access, not clinical individualization. That is understandable — the branded products were unaffordable for many patients — but it is not what the compounding framework was designed for, and the regulatory pushback was predictable.
Second, the response to that boom should not collapse into a blanket dismissal of compounding. The same channel that produced questionable bulk GLP-1 copies is also the channel that produces the allergy-safe pediatric suspension, the intermediate hormone dose, and the individualized formulation a specific patient genuinely needs. Regulation should distinguish those cases, and thoughtful compounders already do.
Future Research Directions
- Post-market safety data comparing compounded and branded GLP-1 outcomes at population scale.
- Standardized analytical documentation frameworks for peptide compounding beyond current USP guidance.
- Clearer patient-facing disclosure standards so consumers can distinguish 503A patient-specific work from de facto manufacturing.
- Updated bulks-list processes that keep pace with the pace of new peptide research without opening safety gaps.
FAQ
What is the difference between compounded and generic? A generic is an FDA-approved drug from a different manufacturer that must demonstrate bioequivalence to the branded version. A compounded preparation is made per prescription by a pharmacy and is not FDA-approved as a finished product.
Are compounded medications FDA-approved? No. Individual compounded preparations are not FDA-approved. The pharmacy or facility that produces them is regulated (state boards for 503A; FDA registration and cGMP for 503B), but the finished preparation itself is not an approved drug.
Is compounded semaglutide still legal in 2026? Large-scale replication compounding of semaglutide is not broadly permitted now that the FDA declared the shortage resolved. Patient-specific compounding remains possible only when a documented individualized clinical reason exists that the commercial product cannot address. Rules continue to evolve.
How do I know a compounded product is what it claims to be? Ask for the Certificate of Analysis for the specific lot, confirm third-party analytical testing, verify 503A or 503B status, and confirm USP <797>/<800> compliance for sterile preparations.
Are 503B facilities safer than 503A pharmacies? Not automatically, but they operate under cGMP and FDA inspection rather than state pharmacy board oversight, which is a stricter manufacturing standard. Both tiers include high- and low-quality operators.
Can any peptide be compounded? No. Peptides eligible for compounding are those on the FDA's bulks lists or that meet other §503A/§503B pathways. Several peptides that were previously common are no longer available through compounding.
How should I evaluate a telehealth clinic that offers compounded peptides? Ask which pharmacy fills the prescription, whether it is 503A or 503B, and request Certificates of Analysis. Distinguish clinics that individualize dosing from clinics that use "personalization" as marketing language for what is effectively a fixed protocol.
Get the Weekly Research Dispatch
One email each week featuring evidence-based health research, longevity insights, and performance science.
References
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA
- Drug Quality and Security Act (DQSA), Pub. L. No. 113–54 (2013). Congress.gov
- U.S. FDA. Bulk Drug Substances Used in Compounding Under Section 503A/503B. FDA
- U.S. FDA. FDA's Decision on Removal of Tirzepatide from the Drug Shortage List. 2024. FDA
- Outterson K. Regulating compounding pharmacies after NECC. N Engl J Med. 2012;367(21):1969–1972. PubMed
- United States Pharmacopeia. General Chapters <795>, <797>, <800>. USP
